| ［1］ |
Shi M, Shahsafaei A, Liu C, et al. Enhancer of zeste homolog 2 is widely expressed in T⁃cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases［J］. Leuk Lymphoma, 2015,56（7）:2087⁃2091. doi: 10.3109/10428194.2014.968780.
|
| ［2］ |
Müller J, Hart CM, Francis NJ, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex［J］. Cell, 2002,111（2）:197⁃208.
|
| ［3］ |
Ueda K, Yoshimi A, Kagoya Y, et al. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16［J］. Cancer Sci, 2014,105（5）:512⁃519. doi: 10.1111/cas.12386.
|
| ［4］ |
Li Y, Li D, Zhao M, et al. Long noncoding RNA SNHG6 regulates p21 expression via activation of the JNK pathway and regulation of EZH2 in gastric cancer cells［J］. Life Sci, 2018,208:295⁃304. doi: 10.1016/j.lfs.2018.07.032.
|
| ［5］ |
Zhang F, Peng H. LncRNA⁃ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27［J］. J Orthop Surg Res, 2017,12（1）:103. doi: 10.1186/s13018⁃017⁃0599⁃7.
|
| ［6］ |
Han L, Zhang HC, Li L, et al. Downregulation of long noncoding RNA HOTAIR and EZH2 induces apoptosis and inhibits proliferation, invasion, and migration of human breast cancer cells［J］. Cancer Biother Radiopharm, 2018,33（6）:241⁃251. doi: 10.1089/cbr.2017.2432.
|
| ［7］ |
Daures M, Idrissou M, Judes G, et al. A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2［J］. Oncotarget, 2018,9（34）:23413⁃23425. doi: 10.18632/oncotarget. 25182.
|
| ［8］ |
Chen Z, Yang P, Li W, et al. Expression of EZH2 is associated with poor outcome in colorectal cancer［J］. Oncol Lett, 2018,15（3）:2953⁃2961. doi: 10.3892/ol.2017.7647.
|
| ［9］ |
Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro⁃ectodermal differentiation［J］. Proc Natl Acad Sci U S A, 2009,106（13）:5324⁃5329. doi: 10.1073/pnas.0810759106.
|
| ［10］ |
Chang CJ, Yang JY, Xia W, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1⁃β⁃catenin signaling［J］. Cancer Cell, 2011,19（1）:86⁃100. doi: 10. 1016/j.ccr.2010.10.035.
|
| ［11］ |
Xiang S, Zou P, Tang Q, et al. HOTAIR⁃mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I⁃inhibited growth of castration⁃resistant prostate cancer cells in vitro and in vivo［J］. Biochim Biophys Acta Gen Subj, 2018,1862（3）:589⁃599. doi: 10.1016/j.bbagen.2017.12.001.
|
| ［12］ |
Sander S, Bullinger L, Klapproth K, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR⁃26a［J］. Blood, 2008,112（10）:4202⁃4212. doi: 10.1182/blood⁃2008⁃03⁃147645.
|
| ［13］ |
Jiang M, Xu B, Li X, et al. O⁃GlcNAcylation promotes colorectal cancer metastasis via the miR⁃101⁃O⁃GlcNAc/EZH2 regulatory feedback circuit［J］. Oncogene, 2019,38（3）:301⁃316. doi: 10. 1038/s41388⁃018⁃0435⁃5.
|
| ［14］ |
Wei Y, Chen YH, Li LY, et al. CDK1⁃dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells［J］. Nat Cell Biol, 2011,13（1）:87⁃94. doi: 10.1038/ncb2139.
|
| ［15］ |
Geng J, Li X, Zhou Z, et al. EZH2 promotes tumor progression via regulating VEGF⁃A/AKT signaling in non⁃small cell lung cancer［J］. Cancer Lett, 2015,359（2）:275⁃287. doi: 10.1016/j.canlet.2015.01.031.
|
| ［16］ |
林璐慧. 组蛋白甲基转移酶EZH2在血液肿瘤中表观遗传调控作用的研究进展［J］.白血病·淋巴瘤, 2014,23（3）:185⁃188. doi: 10.3760/cma.j.issn.1009⁃9921.2014.03.019.
|
| ［17］ |
Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 （Tyr641） in follicular and diffuse large B⁃cell lymphomas of germinal⁃center origin［J］. Nat Genet, 2010,42（2）:181⁃185. doi: 10.1038/ng.518.
|
| ［18］ |
Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation［J］. Blood, 2011,117（8）:2451⁃2459. doi: 10.1182/blood⁃2010⁃11⁃321208.
|
| ［19］ |
Song X, Zhang L, Gao T, et al. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation［J］. Biomed Pharmacother, 2016,81:288⁃294. doi: 10.1016/j.biopha.2016.04.019.
|
| ［20］ |
Visser HP, Gunster MJ, Kluin⁃Nelemans HC, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma［J］. Br J Haematol, 2001,112（4）:950⁃958.
|
| ［21］ |
Abdalkader L, Oka T, Takata K, et al. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B⁃ and T/NK⁃cell neoplasms［J］. Pathology, 2016,48（5）:467⁃482. doi: 10.1016/j.pathol.2016.05.002.
|
| ［22］ |
Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer/T⁃cell lymphoma confers growth advantage independently of histone methyltransferase activity［J］. Blood, 2013,121（22）:4512⁃4520. doi: 10.1182/blood⁃2012⁃08⁃450494.
|
| ［23］ |
Yi S, Sun J, Qiu L, et al. Dual Role of EZH2 in cutaneous anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment［J］. J Invest Dermatol, 2018,138（5）:1126⁃1136. doi: 10.1016/j.jid.2017.10. 036.
|
| ［24］ |
Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia［J］. Nat Med, 2012,18（2）:298⁃301. doi: 10.1038/nm.2651.
|
